JHN

(3~{R})-3-[[4-(3,4-dihydro-2~{H}-pyrano[2,3-c]pyridin-6-ylmethylamino)piperidin-1-yl]methyl]-1,4,7-triazatricyclo[6.3.1.0^{4,12}]dodeca-6,8(12),9-triene-5,11-dione

Created:2019-02-26
Last modified:  2019-03-13

Help

Find related ligands:

Chemical Details

Formal Charge0
Atom Count61
Chiral Atom Count1
Bond Count66
Aromatic Bond Count6
2D diagram of JHN
Toggle HydrogenToggle Labels

Chemical Component Summary

Name(3~{R})-3-[[4-(3,4-dihydro-2~{H}-pyrano[2,3-c]pyridin-6-ylmethylamino)piperidin-1-yl]methyl]-1,4,7-triazatricyclo[6.3.1.0^{4,12}]dodeca-6,8(12),9-triene-5,11-dione
Systematic Name (OpenEye OEToolkits)(3~{R})-3-[[4-(3,4-dihydro-2~{H}-pyrano[2,3-c]pyridin-6-ylmethylamino)piperidin-1-yl]methyl]-1,4,7-triazatricyclo[6.3.1.0^{4,12}]dodeca-6,8(12),9-triene-5,11-dione
FormulaC24 H28 N6 O3
Molecular Weight448.518
TypeNON-POLYMER

Chemical Descriptors

TypeProgramVersionDescriptor
SMILESCACTVS3.385O=C1C=CC2=C3N1C[CH](CN4CCC(CC4)NCc5cc6CCCOc6cn5)N3C(=O)C=N2
SMILESOpenEye OEToolkits2.0.7c1c2c(cnc1CNC3CCN(CC3)CC4CN5C(=O)C=CC6=C5N4C(=O)C=N6)OCCC2
Canonical SMILESCACTVS3.385 O=C1C=CC2=C3N1C[C@@H](CN4CCC(CC4)NCc5cc6CCCOc6cn5)N3C(=O)C=N2
Canonical SMILESOpenEye OEToolkits2.0.7 c1c2c(cnc1CNC3CCN(CC3)C[C@@H]4CN5C(=O)C=CC6=C5N4C(=O)C=N6)OCCC2
InChIInChI1.03 InChI=1S/C24H28N6O3/c31-22-4-3-20-24-29(22)15-19(30(24)23(32)13-27-20)14-28-7-5-17(6-8-28)25-11-18-10-16-2-1-9-33-21(16)12-26-18/h3-4,10,12-13,17,19,25H,1-2,5-9,11,14-15H2/t19-/m1/s1
InChIKeyInChI1.03 PZFAZQUREQIODZ-LJQANCHMSA-N

Drug Info: DrugBank

DrugBank data are sourced from datasets licensed under a Creative Common's Attribution-NonCommercial 4.0 International License
DrugBank IDDB12134 
NameGepotidacin
Groups
  • approved
  • investigational
DescriptionGepotidacin is a first-in-class triazaacenaphthylene antibacterial targeting bacterial DNA gyrase and topoisomerase IV.[L52685] Its target is similar to that of fluoroquinolone antibacterials - e.g. [ciprofloxacin] - while being structurally and pharmacologically distinct.[A273755] By inhibiting two distinct bacterial enzymes, a lower potential for the development of resistance to gepotidacin is expected.[L52680] In March 2025, gepotidacin was approved by the FDA for the treatment of uncomplicated urinary tract infections in select patients.[L52680,L52685] In December later the same year, the FDA approved another indication for gepotidacin for the treatment of uncomplicated urogenital gonorrhea. [L54803]
Synonyms
  • Gepotidacin hydrochloride
  • Gepotidacin mesylate
  • Gepotidacin
Brand NamesBlujepa
IndicationGepotidacin is indicated for the treatment of female patients ≥12 years of age weighing ≥40 kilograms with uncomplicated urinary tract infections caused by _Escherichia coli_, _Klebsiella pneumoniae_, _Citrobacter freundii_ complex, _Staphylococcus saprophyticus_, or _Enterococcus faecali_.[L52685] Additionally, Gepotidacin is indicated for the treatment of uncomplicated urogenital gonorrhea in adult and pediatric patients 12 years of age and older weighing at least 45 kilograms who have limited or no alternative treatment options. [L54843] To reduce the development of drug-resistant bacteria and maintain the effectiveness of gepotidacin and other antibacterial drugs, gepotidacin should be used only to treat infections that are proven or strongly suspected to be caused by susceptible bacteria.
Categories
  • Antibacterials for Systemic Use
  • Antiinfectives for Systemic Use
  • BCRP/ABCG2 Substrates
  • Cytochrome P-450 CYP3A Substrates
  • Cytochrome P-450 CYP3A4 Substrates
ATC-CodeJ01XX13
CAS number1075236-89-3

Drug Targets

DrugBank data are sourced from datasets licensed under a Creative Common's Attribution-NonCommercial 4.0 International License
NameTarget SequencePharmacological ActionActions
DNA topoisomerase 4 subunit AMSDMAERLALHEFTENAYLNYSMYVIMDRALPFIGDGLKPVQRRIVYAMS...unknowninhibitor
DNA gyrase subunit AMSDLAREITPVNIEEELKSSYLDYAMSVIVGRALPDVRDGLKPVHRRVLY...unknowninhibitor
AcetylcholinesteraseMRPPQCLLHTPSLASPLLLLLLWLLGGGVGAEGREDAELLVTVRGGRLRG...unknowninhibitor
DNA topoisomerase 2-betaMAKSGGCGAGAGVGGGNGALTWVTLFDQNNAAKKEESETANKNDSSKKLS...unknowninhibitor
DNA topoisomerase 2-alphaMEVSPLQPVNENMQVNKIKKNEDAKKRLSVERIYQKKTQLEHILLRPDTY...unknowninhibitor
View More
Drug Info/Drug Targets: DrugBank 3.0: a comprehensive resource for 'omics' research on drugs. Knox C, Law V, Jewison T, Liu P, Ly S, Frolkis A, Pon A, Banco K, Mak C, Neveu V, Djoumbou Y, Eisner R, Guo AC, Wishart DS. Nucleic Acids Res. 2011 Jan; 39 (Database issue):D1035-41. | PMID:21059682

Related Resource References

Resource NameReference
PubChem 25101874
ChEMBL CHEMBL3317856